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Abstract
Rimonabant is the first CB1 receptor inhibitor available in the Brazilian market. This new drug has
been approved for the treatment of obese or overweight patients associated with cardiovascular
risk factors. In this article it is compared the effects of rimonabant treatment in obese patients with
cardiovascular risk factors to usual obesity pharmacological treatment.
Background
Rimonabant is the first CB1 receptor inhibitor available in
the Brazilian market. This new drug has been approved for
the treatment of obese or overweight patients associated
with cardiovascular risk factors. This way, it is important
to emphasize that the Rimonabant drug has not been
approved for the treatment of patients with isolated cardi-
ovascular risks, but rather for the treatment of excess
weight. It is questioned whether the effect of Rimonabant
regarding cardiovascular risk factors (lowering blood pres-
sure, promoting lipid profile improvement, and reduction
of glycated hemoglobin) is related to weight loss, or
whether risk factor improvement is superior to other anti-
obesity medications or to weight loss based on life style
change.
Studies show that Rimonabant-driven weight loss is supe-
rior compared to placebo. However, to date, there are no
studies which compare Rimonabant to other anti-obesity
drugs or intensive life style change, such as the Diabetes
Prevention Programme (DPP). The DPP compared the
effects of the use of metformin to the change in life style
and it was shown that the latter resulted in greater weight
loss and cardiovascular risk factor improvement.
Next, the effects of Rimonabant over each cardiovascular
risk will be discussed.
Blood Pressure
Rimonabant has been announced as the drug to result in
blood pressure reduction. The study to show the most rel-
evant blood pressure drop was the RIO-Lipids, which
evinced a 2.1-mmHg in systolic BP in the Rimonabant
group, and a 1.7-mmHg drop upon the subtraction of the
placebo effect [1]. Although statistically relevant, the little
clinical significance of this value leads to the conclusion
that the effect of this drug on blood pressure is null.
Lipids
Regarding lipids in multivariate analyses, there seems to
be a non-weight-dependent percentage of improvement.
The use of Rimonabant compared to placebo resulted in a
difference of nearly 12% in HDL-cholesterol increase and
a nearly 12% increase in triglycerides levels. The presenta-
tion of the effect of the drug over a certain variable
through a percentage value, although useful from the sta-
tistical standpoint, might many times overshadow the
magnitude of the actual effect possibly expected from the
drug, in absolute numbers. Therefore, it is worth observ-
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ing the effect caused by Rimonabant, on average, in abso-
lute numbers over lipids. In the RIO-Lipids study, the
increase in HDL-cholesterol was 3.13 mg/dL greater than
the placebo, on average, on the Rimonabant group[1].
The RIO-Diabetes study shows, as a result, an average
improvement of 3.9 mg/dL in men upon the subtraction
of the placebo effect[2]. The residual impact of Rimona-
bant over HDL, i.e., the post-adjustment effect for weight
loss, was accountable for 57% of the improvement. Again,
analyzing in absolute numbers, it was found that Rimona-
bant, regardless of the weight loss, led to an average 2.22
mg/dL increase in HDL. Analyzing the group that pre-
sented weight loss under 5% of the initial weight, the
Rimonabant group presented a 1.66% increase in HDL,
on average. The issue brought about when assessing the
effect of the drug, regardless of the weight, is whether the
improvement is clinically significant and if it can be con-
verted into genuine reduction in cardiovascular risk.
Comparing Rimonabant to other drugs which also pro-
mote weight loss like sibutramine (an anti-obesity drug,
whose effect is similar to Rimonabant, except for its non-
effect over the endocanabinnoid system), within a year, it
was observed that weight loss was accompanied by a 15%
increase in HDL cholesterol[3]. This improvement is due
to weight loss, once this is the only effect of the drug.
Among patients who lost less than 5% of their weight, the
Rimonabant group presented a 5.2% reduction in triglyc-
erides, on average, compared to placebo. Once again, the
question is raised as to the clinical meaning of this reduc-
tion.
These data lead us to question if the weight loss induced
by Rimonabant brings any additional clinically significant
benefit when compared to weight loss by any other anti-
obesity drug, or even due to changes in life style.
Studies published to date do not demonstrate an
improvement in LDL, which is considered the cholesterol
fraction to be more closely linked to cardiovascular risk.
Glycemic control
The two studies available and published with Rimona-
bant in diabetic patients, Rio-Diabetes and Serenade,
showed an improvement in glycated hemoglobin of
nearly 0.5% compared to placebo[4].
Anderson et col. published in 2003 a meta-analysis of var-
ious studies which interfered in diabetic patients'
weight[5]. It demonstrated that, regarding baseline values,
there was an improvement in several parameters such as
the reduction of fasting glycemia, cholesterol, LDL, trig-
lycerides and systolic and diastolic blood pressure. The
only factor where an improvement was not observed was
in HDL, although some studies revealed a worsening of
the condition. The conclusion of the meta-analysis was
that weight reduction in diabetic patients, regardless of
the treatment, improves cardiovascular risk, except HDL,
in a comparable magnitude to that observed with
Rimonabant. In this meta-analysis, no mentions were
made to glycated hemoglobin. In a meta-analysis of stud-
ies conducted with sibutramine, considering glycated
hemoglobin as a parameter, a substantial variability was
observed in the decrease of HbA1c (0 to 1.34%), with an
average reduction of 0.28%. Of the studies included, only
three presented statistical significance[6]. Considering
these data, it is possible that Rimonabant is more effective
in reducing glycated hemoglobin than weight loss alone.
However, the change in stratified HbA1c by weight loss
was not published, which would lead us to conclude if
there is actually an improvement beyond weight loss.
Thus, the doubt remains whether the 0.5% reduction in
glycated hemoglobin is weight-dependent or if this reduc-
tion goes beyond weight loss.
Inflammatory Markers
Regarding inflammatory markers, which are currently also
considered cardiovascular risk markers, their improve-
ment was also observed in studies with Rimonabant. In
the RIO-Lipids study, there was a 29% reduction in the C
reactive protein (CRP), and in the RIO-Diabetes study, the
CRP reduction was 26% [2]. Recently, Copolla et cols.
demonstrated that the reduction of BMI from 34.4 to 30.1
on average with a multidisciplinary treatment in the
course of one year was followed by a 40% drop in CRP
levels[7], i.e., effective weight loss may improve CRP lev-
els in greater magnitude than with Rimonabant.
Considering adiponectin, the RIO-Lipids study showed an
increase in adiponectin to 1.5 μg/ml, upon subtraction of
the placebo effect. A multivariate analysis demonstrated
that 57% of this effect would be a result of the blockage of
the CB1 receptor rather than weight loss. However, the
same study already previously mentioned, which demon-
strated the reduction of CRP with weight loss, also evalu-
ated adiponectin, having observed an average increase of
58.8% in adiponectin[7].
Also, despite the low levels of adiponectin having been
related to greater cardiovascular risk, it is worth pointing
out that the clinical significance of adiponectin increase is
yet undefined. Glitazones, sensitizers of the insulin action
which increase adiponectin levels more remarkably than
Rimonabant[8], still have not proven to reduce cardiovas-
cular risk.
It is known that other drugs, such as glimepiride, are capa-
ble of increasing adiponectin levels up to 50%, despite
their lack of effect over body weight[9].Diabetology & Metabolic Syndrome 2009, 1:18 http://www.dmsjournal.com/content/1/1/18
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Another factor that results in an increase in adiponectin
levels is physical exercise, possibly due to an improve-
ment in insulin resistance. In a study where physical exer-
cise was performed through a period of 10 weeks, without
leading to weight loss, the average adiponectin level
increased over 100%[10]. These data suggest that the
observed adiponectin increase with Rimonabant is infe-
rior to that obtained with the above described interven-
tions. Also, once again, the significance of this increase is
still undefined.
Another factor worth emphasizing is the way this datum
is presented, both in publications and in product promo-
tional materials - at times, it conveys the impression that
the magnitude of the event is greater than what is verified
in absolute numbers. As an example, the information that
45% of the improvement in HDL observed in studies with
Rimonabant is not explained by weight loss sounds more
important than the information that a 3.6% increase in
HDL induced by Rimonabant is not explained by weight
loss, specially considering that this increase would be
nearly 1.4 mg/dL in absolute numbers. Also, and once
again, the clinical significance of this change is still ques-
tioned.
Atheromatous plaque
The Stradivarius study recently published, analyzed the
effect of the use of Rimonabant over the atheromatous
plaque, which was being expected as it was the first study
to propose to assess if the use of Rimonabant did actually
result in the reduction of the atheromatous plaque evalu-
ated by the coronary ultrasound. In this study, according
to the primary endpoint, the percentage volume of the
atheromatous plaque did not show an improvement com-
pared to placebo. The only significant improvement
among Rimonabant users compared to placebo was
observed in the subgroup that was not given statins[11].
Considering that most patients to whom Rimonabant is
indicated have high cardiovascular risk, these patients
must already be using statins, i.e., this subgroup probably
corresponds to a small share of the high cardiovascular
risk population.
Safety
A meta-analysis of the safety and efficacy of Rimonabant
was recently published, evaluating the data of four studies
with Rimonabant, at a total of 4105 patients. The average
weight loss was 4.7 kg, having subtracted the placebo
effect; patients using Rimonabant had a chance five times
greater of presenting weight loss over 2%. The main
adverse effects reported, which in reality is the greatest
concern of us physicians, were of psychiatric nature[12].
One of endocannabinnoid agonists is known as ananda-
mide. The term ananda, from Sanskrit, means "internal
bliss". The term might reveal well some of the physiolog-
ical functions of the endocannabinoid system in the cen-
tral nervous system. Di Marzo summarized some of these
functions as "feeling less pain, controlling one's move-
ments, relaxing, eating, forgetting, sleeping and protect-
ing"[13]. This way, it is expected that the intervention in
this system be followed by other effects rather than the
reduction in food intake.
Objectively, the relative risk of a patient using Rimona-
bant developing an adverse event is 1.4, and the NNH
(number needed to harm), i.e., the number of patients
treated so that one patient will present any adverse event,
is 25. For a serious adverse event, the NNH is 59. The rel-
ative risk of a patient taking Rimonabant to discontinue
the medication due to depression is 2.5. For every 49
patients treated, one discontinued the treatment due to
depression, and for every 166 patients treated, one had to
stop due to anxiety[12].
Final considerations
It is undebatable that weight loss induced by Rimonabant
is clinically significant and that it results in a metabolic
profile. However, weight loss cannot be mistaken for
other more clinically relevant endpoints, and the greatest
concern and expectation of the medical community
revolves around cardiovascular risk, whose reduction still
has not been demonstrated. The termination of other
ongoing studies, the main being the CRESCENDO study,
will show if the drug genuinely brings effect to cardiovas-
cular mortality, which in the end is what matters the most
to us, and clarify if this effect adds to that of drugs which
present a well established cardiovascular benefit, such as
statins.
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